UK Clinical randomised trial of treating fibroids with either embolisation or myomectomy to measure the effect on quality of life among women wishing to avoid hysterectomy (womb removal) (the FEMME study)
Aim :To compare which treatment has the biggest effect on women’s quality of life
The FEMME trial’s primary outcome is the quality of life women with symptomatic uterine fibroids experience two years after they have been treated with either UAE (Uterine Artery Embolisation to shrink fibroids) or myomectomy (fibroid removal) , as measured by the disease-specific Uterine Fibroid Symptom Quality-of-Life (UFS-QoL) questionnaire.
Hospital centres across UK. Birmingham was the main co-ordinating centre.
Recruitment to FEMME has now closed. The results and patient surveys are being collected.
If you have any questions about FEMME then please don’t hesitate to contact Bill, the trial coordinator, by email (email@example.com) or telephone (0121 414 8335).